Parsing the Fed Minutes
Airtime: Wed. Jul. 14 2010 | 2:02 PM ET
About half of the FOMC now sees risks tilted to the downside, reports CNBC’s Steve Liesman. Zane Brown, of Lord Abbett, and James Bianco, of Bianco Research, share their views.
Airtime: Wed. Jul. 14 2010 | 2:02 PM ET
About half of the FOMC now sees risks tilted to the downside, reports CNBC’s Steve Liesman. Zane Brown, of Lord Abbett, and James Bianco, of Bianco Research, share their views.
Fitch Ratings downgraded Spain’s credit rating by one notch on Friday, with Win Tin, Brown Brothers Harriman sr. currency strategist.
Looking at the market, since Monday’s follow-through day, the market and a batch of leading stocks, steadily rallied which is a healthy sign. The fact that we have not seen any serious distribution days show up since Monday’s FTD bodes well for this nascent rally. It is also a welcome sign to see the market continue to improve as investors digest the latest round of stronger than expected economic and earnings data. Remember that now that a new rally has been confirmed, the window is open to start buying high quality breakouts. Trade accordingly.
Insight on the SEC’s high-level investigations, with Robert Khuzami, SEC director of enforcement.
The environment for a cyclical bull market is in place, says Ajay Kapur, head of equity strategy, Asia at Deutsche Bank. However, he tells CNBC’s Martin Soong and Bernard Lo that this is risky entry point for investors.
Study Identifies Heart Risks in Glaxo’s Avandia. Dr. Steven Nissen, of the Cleveland Clinic, authored a controversial study identifying heart risks in GlaxoSmithKline’s Avandia diabetes drug. He talks to CNBC’s Mike Huckman.
Airtime: Mon. Aug. 16 2010 | 7:16 PM ET
A look at what big names like Warren Buffett are holding, with CNBC’s Tyler Mathisen.